210 related articles for article (PubMed ID: 14718785)
1. Current status of antibody therapy for breast cancer.
Toi M; Takada M; Bando H; Toyama K; Yamashiro H; Horiguchi S; Saji S
Breast Cancer; 2004; 11(1):10-4. PubMed ID: 14718785
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.
Bernard-Marty C; Lebrun F; Awada A; Piccart MJ
Drugs; 2006; 66(12):1577-91. PubMed ID: 16956305
[TBL] [Abstract][Full Text] [Related]
5. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
6. Her2 and trastuzumab in breast cancer.
Horton J
Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040
[No Abstract] [Full Text] [Related]
7. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer.
Spigel DR; Burstein HJ
Clin Breast Cancer; 2003 Dec; 4(5):329-37; discussion 338-9. PubMed ID: 14715107
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab: designer drug or fashionable fad?
Freebairn AJ; Last AJ; Illidg TM
Clin Oncol (R Coll Radiol); 2001; 13(6):427-33. PubMed ID: 11824879
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor.
Simonds HM; Miles D
Expert Opin Biol Ther; 2007 Apr; 7(4):487-91. PubMed ID: 17373900
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-based combination therapy for breast cancer.
Montemurro F; Valabrega G; Aglietta M
Expert Opin Pharmacother; 2004 Jan; 5(1):81-96. PubMed ID: 14680438
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).
Umemura S; Sakamoto G; Sasano H; Tsuda H; Akiyama F; Kurosumi M; Tokuda Y; Watanabe T; Toi M; Hasegawa T; Osamura RY
Breast Cancer; 2001; 8(4):316-20. PubMed ID: 11791124
[TBL] [Abstract][Full Text] [Related]
12. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL; Keam SJ
BioDrugs; 2006; 20(4):259-62. PubMed ID: 16831025
[TBL] [Abstract][Full Text] [Related]
14. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
15. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
Bedard PL; de Azambuja E; Cardoso F
Curr Cancer Drug Targets; 2009 Mar; 9(2):148-62. PubMed ID: 19275756
[TBL] [Abstract][Full Text] [Related]
16. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
Brufsky A; Lembersky B; Schiffman K; Lieberman G; Paton VE
Clin Breast Cancer; 2005 Aug; 6(3):247-52. PubMed ID: 16137436
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
18. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
19. Improving the efficacy of trastuzumab in breast cancer.
Suzuki E; Toi M
Cancer Sci; 2007 Jun; 98(6):767-71. PubMed ID: 17428260
[TBL] [Abstract][Full Text] [Related]
20. Antibodies as molecular target-based therapy: trastuzumab.
Tokuda Y
Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
